Nanomi

Over Nanomi: Nanomi ontwikkelt Nano en Microdeeltjes voor de farmaceutische industrie door middel van onze microfluidic Monosphere Technology. Wij zijn het “center of excellence for complex injectables” van Lupin ltd, een internationaal Indiaas farmaceutisch concern. Nanomi is een internationale, hightech omgeving met een leuke, informele werksfeer. Company Profile: Nanomi, based in Oldenzaal, is a drug delivery company developing pharmaceutical products based on nano- and microparticles. These particles are developed by using Nanomi’s microfluidic Monosphere Technology, enabling the manufacturing of very unique and uniform custom-made particles for a broad range of pharmaceutical products. In 2014 Nanomi was acquired by Lupin and became its center of excellence for complex injectables. Nanomi offers a highly innovative as well as dynamic environment and benefits from its parent company that was founded in 1968. Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INSURERS TAKE AIM AT BIG PHARMA. THIS SMALL-CAP STOCK STANDS TO WIN.

Fool.com | January 30, 2020

news image

The premise of generic drugs was simple enough. Branded medicines protected by a patent tend to be overpriced, but the equivalent therapy made by other companies once a patent expires should lead to price-lowering competition. As it turns out, however, generic drugs have become overpriced as well. That's the stance the state of California has taken, anyway, with Governor Gavin Newsom announcing early this month the state is planning to launch its own prescription drug label. The Blue Cross B...

Read More

J&J LAUNCHES ‘MULTI-PRONGED’ CORONAVIRUS RESPONSE

PharmaTimes | January 30, 2020

news image

The company has initiated efforts to broadly collaborate with others in order to screen a library of antiviral therapies, hoping to identify compounds with antiviral activity against the virus – which is also known as 2019-nCoV or Wuhan coronavirus. Using its AdVac and PER.C6 technologies - the same technologies that were used in the development and manufacturing of Janssen's investigational Ebola vaccine - J&J has revealed plans to try and rapidly upscale production of the optimal...

Read More

GLOBAL ASEPTIC PACKAGING FOR THE PHARMACEUTICAL MARKET COMPETITIVE LANDSCAPE OUTLOOK TO 2025

Fashion Trends Now | April 09, 2020

news image

The research report on “Global Aseptic Packaging for the Pharmaceutical Market” serves in-depth analysis on latest and upcoming market scenario of Aseptic Packaging for the Pharmaceutical in the appraisal period, 2020-2025. The report survey Aseptic Packaging for the Pharmaceutical market growth past, sales channel, players profiled in Aseptic Packaging for the Pharmaceutical industry, product type and application market share and Aseptic Packaging for the Pharmaceutical regional sco...

Read More

PHARMACY MARKET

ALCAMI ADDS ADDITIONAL FORMULATION DEVELOPMENT CAPABILITIES

Alcami Corporation | March 02, 2022

news image

Alcami, a U.S.-based pharmaceutical contract development and manufacturing organization announced the addition of a 3,800 ft² Non-GMP Formulation Development Laboratory (FDL). The dedicated Non-GMP formulation development space, which is co-located within the same facility as Alcami's parenteral manufacturing operation that offers four isolator filling lines for liquid and lyophilized products, is ready to support customers with Preclinical and Clinical development programs. Read More

news image

INSURERS TAKE AIM AT BIG PHARMA. THIS SMALL-CAP STOCK STANDS TO WIN.

Fool.com | January 30, 2020

The premise of generic drugs was simple enough. Branded medicines protected by a patent tend to be overpriced, but the equivalent therapy made by other companies once a patent expires should lead to price-lowering competition. As it turns out, however, generic drugs have become overpriced as well. That's the stance the state of California has taken, anyway, with Governor Gavin Newsom announcing early this month the state is planning to launch its own prescription drug label. The Blue Cross B...

Read More
news image

J&J LAUNCHES ‘MULTI-PRONGED’ CORONAVIRUS RESPONSE

PharmaTimes | January 30, 2020

The company has initiated efforts to broadly collaborate with others in order to screen a library of antiviral therapies, hoping to identify compounds with antiviral activity against the virus – which is also known as 2019-nCoV or Wuhan coronavirus. Using its AdVac and PER.C6 technologies - the same technologies that were used in the development and manufacturing of Janssen's investigational Ebola vaccine - J&J has revealed plans to try and rapidly upscale production of the optimal...

Read More
news image

GLOBAL ASEPTIC PACKAGING FOR THE PHARMACEUTICAL MARKET COMPETITIVE LANDSCAPE OUTLOOK TO 2025

Fashion Trends Now | April 09, 2020

The research report on “Global Aseptic Packaging for the Pharmaceutical Market” serves in-depth analysis on latest and upcoming market scenario of Aseptic Packaging for the Pharmaceutical in the appraisal period, 2020-2025. The report survey Aseptic Packaging for the Pharmaceutical market growth past, sales channel, players profiled in Aseptic Packaging for the Pharmaceutical industry, product type and application market share and Aseptic Packaging for the Pharmaceutical regional sco...

Read More
news image

PHARMACY MARKET

ALCAMI ADDS ADDITIONAL FORMULATION DEVELOPMENT CAPABILITIES

Alcami Corporation | March 02, 2022

Alcami, a U.S.-based pharmaceutical contract development and manufacturing organization announced the addition of a 3,800 ft² Non-GMP Formulation Development Laboratory (FDL). The dedicated Non-GMP formulation development space, which is co-located within the same facility as Alcami's parenteral manufacturing operation that offers four isolator filling lines for liquid and lyophilized products, is ready to support customers with Preclinical and Clinical development programs. Read More